Liza Laws, Author at Labiotech.eu

News and Trends 15 Nov 2022

Aelis Farma’s first trial for cognitive disorder drug for Down Syndrome patients

Aelis Farma has announced positive results from its safety trials in healthy volunteers and the authorization to start the first trial in people with Down syndrome, with AEF0217, its drug candidate for the treatment of cognitive disorders. Aelis Farma is a clinical stage biopharmaceutical company specializing in the development of treatments for brain diseases, made […]

November 15, 2022 - 4 minutesmins - By Liza Laws

Ilya Pharma enrols first patient in diabetic foot ulcer study

More News! 15 Nov 2022

Destiny Pharma’s XF-73 dermal infection project advances to safety study

The second of two planned preclinical safety studies has started for Destiny Pharma’s XF-73 dermal formulation. The company announced the start of an investigational new drug (IND) today (November 15) and is developing the formulation for the prevention of infections associated with open wounds and broken skin including diabetic foot ulcers (DFUs). This second study […]

November 15, 2022 - 2 minutesmins - By Liza Laws

More News! 15 Nov 2022

Sequana Medical has positive results for heart failure therapy drug

Sequana Medical has had some very positive top-line results from a phase 2a study, that the company says reinforces its view that direct sodium removal (DSR) is a potential disease modifying heart failure therapy. The study called SAHARA was testing its first-generation DSR product, DSR 1.0. Data from ten evaluable diuretic-resistant heart failure patients with […]

November 15, 2022 - 3 minutesmins - By Liza Laws

News and Trends 15 Nov 2022

Fooditive takes world first bee-free honey a step closer

Large scale production trials of the first bee-free honey will start in the New Year thanks to Dutch-based ingredients company, Fooditive. The process of mass-producing a bio-identical honey means that the need to intensively farm honeybees will be eliminated and Fooditive aims to beat a scalable, provenanced supply. Not only will it provide the benefits […]

November 15, 2022 - 2 minutesmins - By Liza Laws

More News! 14 Nov 2022

Minoryx and Neuraxpharm form alliance to get rights to new therapy for rare CNS disease

Minoryx Therapeutics and Neuraxpharm Group have announced a strategic alliance for the European rights to a new therapy for rare central nervous system (CNS) disease. The companies have entered into a license agreement for leriglitazone, currently under European Medicines Agency (EMA) review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD). Under the agreement, Minoryx grants Neuraxpharm […]

November 14, 2022 - 3 minutesmins - By Liza Laws

More News! 14 Nov 2022

BioSenic’s autoimmune disease platform adapting to meet unmet medical needs

BioSenic’s systemic autoimmune disease platform, originally designed by Medsenic, is now developing controlled dosages and new formulations adapted to a significant number of important indications with unmet medical needs. BioSenic specializes in serious autoimmune and inflammatory diseases as well as cell repair. The update follows the announcement of the merger between Bone Therapeutics and Medsenic […]

November 14, 2022 - 4 minutesmins - By Liza Laws

News and Trends 14 Nov 2022

Priothera’s Mocravimod improves survival for patients with hematological malignancies

Priothera, a biotechnology company developing its S1P receptor modulator compound Mocravimod, has announced that positive data from a clinical trial reinforces the potential for the drug to improve survival outcomes for patients with hematological malignancies. The study has been evaluating Mocramivod in allogeneic hematopoietic cell transplantation patients and was published in journal Transplantation and Cellular […]

November 14, 2022 - 2 minutesmins - By Liza Laws

News and Trends 14 Nov 2022

EpiEndo gets regulatory approval for first patient study of first non-antibiotic macrolide

EpiEndo Pharmaceuticals, a clinical-stage biopharma company developing therapeutics for chronic inflammatory diseases, has received regulatory approval to begin a phase 2a clinical trial. The trial will be with lead molecule EP395 in COPD (chronic obstructive pulmonary disease) patients, an orally available macrolide or ‘Barriolide,’ with reduced antimicrobial resistance potential. It aims to address the unmet […]

November 14, 2022 - 3 minutesmins - By Liza Laws

More News! 14 Nov 2022

ChromaTwist lands second round of funding for fluorescent dyes for flow cytometry market

ChromaTwist Ltd, a University of Birmingham spinout, has secured £487,000 ($573,000) of equity investment to develop its new class of fluorescent dyes for the flow cytometry reagent market. Existing investors, Angel from angelgroups and the University of Birmingham brought in funds which will allow ChromaTwist to continue product development with industry partners and enable rapid […]

November 14, 2022 - 4 minutesmins - By Liza Laws

News and Trends 10 Nov 2022

SOTIO reveal potential treatment for adults with solid tumors at SITC meeting

SOTIO Biotech has presented preclinical results of its BOXR T cell therapy platform and revealed it indicates a strong clinical path for its first transgene-expressing CAR-T cell as a potential treatment for solid tumors in adults with cancer. The results were presented at the Society for Immunotherapy of Cancer’s (SITC) 37th annual meeting taking place […]

November 10, 2022 - 4 minutesmins - By Liza Laws

News and Trends 10 Nov 2022

Parthenon and ImaginAb enter into license and supply agreement for anti-cancer therapies

Precision oncology company, Parthenon Therapeutics, and ImaginAb Inc., a global biotech have entered into a multi-year, non-exclusive license and supply agreement. Under the agreement terms, Parthenon will use ImaginAb’s CD8 ImmunoPET imaging technology in its phase 1 trial evaluating its lead compound, PRTH-101, which is expected to begin in 2023. ImaginAb is developing 89Zr crefmirlimab […]

November 10, 2022 - 4 minutesmins - By Liza Laws

More News! 10 Nov 2022

Eye disease therapies being developed after Breye Therapeutics’ €4M seed financing

Breye Therapeutics ApS a biopharmaceutical company developing therapies for retinal vascular diseases today (November 10) has closed a seed financing of €4 million led by Novo Holdings and Sound Bioventures. Diabetic retinopathy (DR) affects approximately 30% of all patients with diabetes and is the leading cause of blindness among working-age adults. Age-related macular degeneration (AMD) […]

November 10, 2022 - 4 minutesmins - By Liza Laws

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Liza Laws

Articles by Liza Laws

Aelis Farma’s first trial for cognitive disorder drug for Down Syndrome patients

Destiny Pharma’s XF-73 dermal infection project advances to safety study

Sequana Medical has positive results for heart failure therapy drug

Fooditive takes world first bee-free honey a step closer

Minoryx and Neuraxpharm form alliance to get rights to new therapy for rare CNS disease

BioSenic’s autoimmune disease platform adapting to meet unmet medical needs

Priothera’s Mocravimod improves survival for patients with hematological malignancies

EpiEndo gets regulatory approval for first patient study of first non-antibiotic macrolide

ChromaTwist lands second round of funding for fluorescent dyes for flow cytometry market

SOTIO reveal potential treatment for adults with solid tumors at SITC meeting

Parthenon and ImaginAb enter into license and supply agreement for anti-cancer therapies

Eye disease therapies being developed after Breye Therapeutics’ €4M seed financing

Subscribe to our newsletter to get the latest biotech news!